Japanese pharmaceutical company Astellas Pharma Inc (TSE: 4503) announced on Thursday that its US subsidiary iota Biosciences Inc has received approval from the US Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) for an Early Feasibility Study (EFS).
The EFS is intended to assess the safety and feasibility of an investigational implantable device designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals affected by underactive bladder (UAB).
The FDA has offered a staged approval of the EFS for this novel device. The first stage includes enrolment of three subjects (at least one male and one female). Following successful safety results from Stage 1, the study will be expanded to a total of 10 subjects.
Michel Maharbiz, Ph.D., iota Biosciences' CEO, said: "Current treatment options for underactive bladder are limited, often forcing patients to rely on clean intermittent catheterisation, which can be burdensome and carry risk of complications. Our team has diligently worked on a potential alternative treatment option, achieving concept to IDE approval in less than four years, a remarkable feat that highlights our commitment to patients and innovation. We are excited to advance clinical development and bring this potential new solution closer to those in need."
ICU Medical establishes JV with Otsuka Pharmaceutical Factory
FDA Panel supports IceCure's ProSense Cryoablation for early-stage breast cancer
Naitive Technologies enters strategic agreement with Parvizi Surgical Innovation
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
PharmaNutra signs agreement with strategic consulting firm for US development plan
BD launches advanced Intraosseous Vascular Access System for rapid emergency use
Pulsenmore to supply 25,000 home ultrasound devices to Clalit Health Services
Medtronic announces new, long-term data from SPYRAL HTN-ON MED clinical trial
Senzime unveils next-gen TetraGraph TOF monitor at ANESTHESIOLOGY 2024; US shipments to begin in Q4
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration